Equities research analysts expect Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) to post ($0.56) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for Spring Bank Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.63) and the highest estimate coming in at ($0.52). Spring Bank Pharmaceuticals reported earnings per share of ($0.29) in the same quarter last year, which would suggest a negative year over year growth rate of 93.1%. The company is scheduled to report its next quarterly earnings report on Wednesday, August 7th.

According to Zacks, analysts expect that Spring Bank Pharmaceuticals will report full year earnings of ($2.18) per share for the current financial year, with EPS estimates ranging from ($3.19) to ($1.83). For the next year, analysts forecast that the firm will post earnings of ($2.99) per share, with EPS estimates ranging from ($4.07) to ($2.30). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that cover Spring Bank Pharmaceuticals.

Spring Bank Pharmaceuticals (NASDAQ:SBPH) last posted its earnings results on Monday, April 29th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.20.

A number of equities analysts have weighed in on SBPH shares. Piper Jaffray Companies set a $40.00 price objective on shares of Schlumberger and gave the stock a “buy” rating in a research report on Monday, July 1st. ValuEngine cut shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. Dawson James restated a “buy” rating on shares of Spring Bank Pharmaceuticals in a research report on Monday, May 13th. Cantor Fitzgerald set a $9.00 price objective on shares of Evofem Biosciences and gave the stock a “buy” rating in a research report on Friday, April 12th. Finally, Chardan Capital set a $10.00 price objective on shares of Arcimoto and gave the stock a “buy” rating in a research report on Friday, April 12th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $19.30.

NASDAQ:SBPH traded up $0.06 during trading hours on Friday, reaching $5.12. 38,317 shares of the company were exchanged, compared to its average volume of 57,733. The company has a debt-to-equity ratio of 0.06, a quick ratio of 12.11 and a current ratio of 12.11. The stock has a 50-day moving average of $4.69. The firm has a market cap of $84.19 million, a price-to-earnings ratio of -2.74 and a beta of 0.37. Spring Bank Pharmaceuticals has a twelve month low of $3.58 and a twelve month high of $15.00.

In other Spring Bank Pharmaceuticals news, insider Martin J. Driscoll bought 5,000 shares of Spring Bank Pharmaceuticals stock in a transaction dated Tuesday, May 21st. The stock was acquired at an average cost of $6.63 per share, for a total transaction of $33,150.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Martin J. Driscoll bought 10,000 shares of Spring Bank Pharmaceuticals stock in a transaction dated Wednesday, May 29th. The stock was acquired at an average price of $6.03 per share, with a total value of $60,300.00. The disclosure for this purchase can be found here. Insiders have acquired 42,000 shares of company stock valued at $242,930 over the last 90 days. 15.60% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. raised its position in shares of Spring Bank Pharmaceuticals by 11.8% in the fourth quarter. BlackRock Inc. now owns 675,333 shares of the company’s stock valued at $7,017,000 after buying an additional 71,266 shares during the last quarter. Rhumbline Advisers raised its position in shares of Spring Bank Pharmaceuticals by 65.3% in the fourth quarter. Rhumbline Advisers now owns 16,771 shares of the company’s stock valued at $174,000 after buying an additional 6,623 shares during the last quarter. Northern Trust Corp raised its position in shares of Spring Bank Pharmaceuticals by 0.9% in the fourth quarter. Northern Trust Corp now owns 171,750 shares of the company’s stock valued at $1,785,000 after buying an additional 1,507 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Spring Bank Pharmaceuticals by 5.9% in the fourth quarter. Bank of New York Mellon Corp now owns 43,789 shares of the company’s stock valued at $454,000 after buying an additional 2,430 shares during the last quarter. Finally, BNP Paribas Arbitrage SA raised its position in shares of Spring Bank Pharmaceuticals by 1,395.4% in the first quarter. BNP Paribas Arbitrage SA now owns 2,946 shares of the company’s stock valued at $31,000 after buying an additional 2,749 shares during the last quarter. Institutional investors and hedge funds own 42.93% of the company’s stock.

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of viral infections, inflammatory diseases, and various cancers using small molecule nucleotide platform. Its lead product candidate is inarigivir soproxil for the treatment of chronic hepatitis B virus (HBV).

Featured Article: Momentum Indicators

Get a free copy of the Zacks research report on Spring Bank Pharmaceuticals (SBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.